The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- Myosin wins $2M grant to advance brain cancer treatment MT-125
- In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
- Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
- Overt forms advisory board to guide ovarian cancer therapy push
- Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma
- Enhanced dynamic risk stratification of smoldering multiple myeloma
- Maximizing RRMM strategy time at doctor appointments
- Don’t underestimate organization’s importance in RRMM care
- Embrace the toughest RRMM conversations ASAP
- A lay of the land in evolving RRMM treatment options